安罗替尼与安维汀分别联合化疗治疗非鳞状非小细胞肺癌的疗效及安全性  

Curative effect and safety of Anlotinib and Avastin respectively combined with chemotherapy on treatment of non-squamous non-small cell lung cancer

作　　者：蒙冲[1] 董文[1] 黄奕江[1] 刘凯[1] Meng Chong;Dong Wen;Huang Yijiang;Liu Kai(Department of Respiratory and Critical Care Medicine,Hainan Provincial People’s hospital,Haikou 570311,China)

机构地区：[1]海南省人民医院呼吸与危重医学科,海口570311

出　　处：《临床内科杂志》2020年第11期781-784,共4页Journal of Clinical Internal Medicine

基　　金：北京医卫健康公益基金会资助项目(F3041C)。

摘　　要：目的探讨安罗替尼与安维汀分别联合培美曲赛、顺铂治疗非鳞状非小细胞肺癌(NSCLC)的疗效及安全性。方法将72例接受化疗的非鳞状NSCLC患者随机分为安罗替尼组和安维汀组,各36例,分别予以安罗替尼、安维汀联合培美曲赛、顺铂治疗,21 d为1个周期,2个周期后评价临床疗效。比较两组患者血清血管内皮生长因子(VEGF)、表皮生长因子(EGF)水平、生存质量及不良反应发生情况。结果两组患者的治疗有效率(RR)比较差异无统计学意义(P>0.05),但安罗替尼组患者的疾病控制率(DCR)高于安维汀组(P<0.05)。两组患者治疗后血清VEGF、EGF水平均低于同组治疗前(P<0.05),且治疗后安罗替尼组血清VEGF、EGF水平均低于安维汀组(P<0.05)。治疗后安罗替尼组患者情绪评分高于安维汀组,疼痛、疲劳、呼吸评分均低于安维汀组(P<0.05)。两组患者治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。除安维汀组出现Ⅲ级胃肠道反应、Ⅲ级骨髓抑制各1例外,安罗替尼组及安维汀组其余不良反应均为Ⅰ~Ⅱ级。结论安罗替尼联合化疗治疗非鳞状NSCLC的临床疗效优于安维汀联合化疗,可能与其有效降低血清VEGF、EGF水平有关,且安罗替尼可提高患者生存质量,安全性尚可。Objective To analyze curative effect and safety of Anlotinib and Avastin respectively combined with pemetrexed and cisplatin on treatment of non-squamous non-small cell lung cancer(NSCLC).Methods Seventy-two patients with non-squamous NSCLC who underwent chemotherapy were randomly divided into Anlotinib group and Avastin group,with 36 cases in each group.Patients in above two groups were treated with Anlotinib or Avastin respectively combined with pemetrexed and cisplatin,take 21 d as 1 cycle,and evaluation of clinical curative effect was performed after 2 cycles.Serum vascular endothelial growth factor(VEGF)and epidermal growth factor(EGF)levels,quality of life and adverse reactions were compared between the two groups.Results There was no significant difference of RR between the two groups(P>0.05),while disease control rate(DCR)of Anlotinib group was significantly higher than that of Avastin group(P<0.05).Serum VEGF and EGF levels in two groups after treatment were significantly lower than those before treatment in the same group(P<0.05),and serum VEGF and EGF levels in Anlotinib group after treatment were significantly lower than those in Avastin group(P<0.05).Emotion scores in Anlotinib group after treatment were significantly higher than those in Avastin group,while pain,fatigue and respiratory scores were significantly lower than those in Avastin group(P<0.05).There were no significant differences of incidence rates of adverse reactions between the two groups during treatment(P>0.05).In addition that there was 1 case with gradeⅢgastrointestinal reactions and 1 case with gradeⅢbone marrow suppression in Avastin group,other adverse reactions in Anlotinib group and Avastin group were all at gradeⅠtoⅡ.Conclusion Clinical curative effect of Anlotinib combined with chemotherapy on treatment of non-squamous NSCLC is better than that of Avastin combined with chemotherapy,which may be related that it can effectively reduce serum VEGF and EGF levels,and Anlotinib can improve patients’quality of life,with ac

关 键 词：安罗替尼 安维汀 非鳞状非小细胞肺癌 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]